Lv2
110 积分 2022-07-23 加入
PROTAC targeted protein degraders: the past is prologue
6天前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
7天前
已完结
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
20天前
已关闭
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
21天前
已关闭
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
1个月前
已完结
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody
1个月前
已完结
Development of Biopharmaceutical Drug-Device Products
1个月前
已完结
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
1个月前
已完结
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
1个月前
已完结
皖公网安备34019202002308
